Teva Pharmaceutical Industries Ltd. ADR logo

Teva Pharmaceutical Industries Ltd. ADR (TEVA)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
32. 83
-0.25
-0.76%
$
40.2B Market Cap
- P/E Ratio
0.34% Div Yield
3,757,008 Volume
- Eps
$ 33.08
Previous Close
Add Transaction
Day Range
32.38 32.98
Year Range
14.99 37.35
Want to track TEVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

Zacks | 5 months ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 6 months ago
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 6 months ago
Teva seeks startups to help solve global pharmaceutical challenges

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceuticals industry.

Reuters | 6 months ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited ( TEVA ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies.

Seekingalpha | 6 months ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

Seekingalpha | 6 months ago
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 6 months ago
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd.

Zacks | 6 months ago
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.

Zacks | 6 months ago
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.

Youtube | 7 months ago
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 7 months ago
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 7 months ago
Loading...
Load More